Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

References

• Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049–53.
   PubMed Web of Science ®Google Scholar
• Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: Clinical implications. Br J Surg 1996;83:107–11.
   PubMed Web of Science ®Google Scholar
• John MJ, Flam MS, Mowry PA, Podolsky WJ, Xavier AM, Wittlinger PS, . Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 1989;63:2397–403.
   PubMed Web of Science ®Google Scholar
• Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, . The ErbB receptors and their ligands in cancer: An overview. Curr Drug Targets 2005;6: 243–57.
   PubMed Web of Science ®Google Scholar
• Jankowski J, Hopwood D, Wormsley KG. Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis 1993;11: 1–11.
   PubMed Web of Science ®Google Scholar
• Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, . ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005;579:4069–75.
   PubMed Web of Science ®Google Scholar
• Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, . Characterization and tissue-specific expression of human LRIG2. Gene 2004;332:35–43.
   PubMed Web of Science ®Google Scholar
• Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003; 312:65–71.
   PubMed Web of Science ®Google Scholar
• Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, Henriksson R. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006;111:238–46.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. J Biol Chem 1996;271:22522–7.
   PubMed Web of Science ®Google Scholar
• Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling – double-edged swords in human cancer? Eur J Cancer 2007;43:676–82.
   PubMed Web of Science ®Google Scholar
• Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, . The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004;279:47050–6.
   PubMed Web of Science ®Google Scholar
• Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, . LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004;16: 3270–81. Epub 2004 Jul 3229.
   Google Scholar
• Shattuck DL, Miller J, Laederich M, Funes M, Petersen H, Carraway KL 3rd, Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007;5:1934–46. Epub 2006 Dec 1918.
   Google Scholar
• Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008;28:39–49.
   PubMed Web of Science ®Google Scholar
• Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 2003;89:1285–9.
   PubMed Web of Science ®Google Scholar
• Tanemura A, Nagasawa T, Inui S, Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: Immunohistochemical analysis for 38 cases. Dermatol Surg 2005;31:423–30.
   PubMed Web of Science ®Google Scholar
• Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, . LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 2008;18:312–7.
   PubMed Web of Science ®Google Scholar
• Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, . Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 2009;29:242–7.
   PubMed Web of Science ®Google Scholar
• Hedman H, Lindström AK, Tot T, Stendahl U, Henriksson R, Hellberg D. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49:812–5.
   PubMed Web of Science ®Google Scholar
• Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 2003;89:1285–9.
   PubMed Web of Science ®Google Scholar
• Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, Hedman H. Characterization and tissue-specific expression of human LRIG2. Gene 2004;332: 35–43.
   PubMed Web of Science ®Google Scholar
• Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, . Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006;111: 238–46.
   PubMed Web of Science ®Google Scholar
• Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, . A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008;7:825–44.
   PubMed Web of Science ®Google Scholar
• Nygren P, Fridborg H, Csoka K, Sundström C, de la Torre M, Kristensen J, Bergh J, . Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994;5:715–20.
   Google Scholar
• Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, . Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001;284:1155–61.
   PubMed Web of Science ®Google Scholar
• Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004;84:157–65.
   PubMed Web of Science ®Google Scholar
• Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008;28:39–49.
   PubMed Web of Science ®Google Scholar
• Guo D, Han L, Shu K, Chen J, Lei T. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. J Huazhong Univ Sci Technolog–Med Sci 2007;27:91–4.
   PubMedGoogle Scholar
• Kii T, Takiuchi H, Kawabe S, Gotoh M, Ohta S, Tanaka T, . Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II III) after concurrent chemoradiotherapy using biopsy specimens. Jpn J Clin Oncol 2007; 37:583–9.
   PubMed Web of Science ®Google Scholar
• Kim LW, Tsung-Teh W, In Seon C, Huamin W, Erika R, Arlene MC, . Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas. Cancer 2007;109:658–67.
   PubMed Web of Science ®Google Scholar
• Wang L-S, Chow K-C, Chi K-H, Liu C-C, Li W-Y, Chiu J-H, . Prognosis of esophageal squamous cell carcinoma: Analysis of clinicopathological and biological factors. Am J Gastroenterol 1999;94:1933–40.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Kumekawa Y, Makino R, Nozawa H, Hirayama Y, Kogo M, Konishi K, . EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010;15:65–72.
   Web of Science ®Google Scholar
• Campen TDaC. Anti-EGFR-targeted therapy for esophageal and gastric cancers: An evolving concept. J Oncol 2009;2009.
   PubMedGoogle Scholar
• Wang KL, Wu T-T, Choi IS, Wang H, Resetkova E, Correa AM, . Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas. Cancer 2007;109:658–67.
   PubMed Web of Science ®Google Scholar
• Stutz MA, Shattuck DL, Laederich MB, Carraway KL, 3rd, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008;27:5741–52.
   PubMed Web of Science ®Google Scholar
• Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281–9.
   PubMed Web of Science ®Google Scholar